Is PERP-B.ST overvalued or undervalued?

PERP-B.ST currently has a P/E ratio of 4.17. Relative to the sector average of 36.50, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Perpetua Medical AB (publ) stock?

Perpetua Medical AB (publ) trades on STO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of PERP-B.ST?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying PERP-B.ST protect my money against local inflation?

Many investors in Latin America buy international stocks like PERP-B.ST to protect their purchasing power. Because PERP-B.ST is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy PERP-B.ST shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is PERP-B.ST a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well PERP-B.ST diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksPERP-B.ST

Perpetua Medical AB (publ)

kr 2.25-kr 0.02-0.88%

STO / SEK

Market cap

kr 19M

P/E

4.2

EPS (TTM)

kr 0.00

Dividend yield

0.00%

Beta

2.07

1Y return

-50.11%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$970,6422021

$965,8872022

$980,6832023

$624,5182024

$2M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.01Low
Current ratio3.76
Cash ratio1.91
Net margin1.7%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

PERP-B.ST4.2
Healthcare sector median36.5
S&P 50022.0

Trades about 89% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.06
Price to book1.16
EPS (TTM)kr 0.00
Payout ratio0%
FCF yield-26.47%

Range & risk

kr 2.00kr 6.00

Trading in the lower third of its 52-week band

Beta2.07

Profile

What Perpetua Medical AB (publ) actually does

Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden specifically tailored for the application and management of injectable medications. Among its principal offerings is DrugLog, a system designed to mitigate errors in pharmacy medication dispensing. Another key product, WasteLog, serves as a device for analyzing and reconciling discarded and returned controlled injectable substances. Additionally, PrepLog, built upon the core technology of DrugLog, integrates with existing prescription or medication management systems to enable the verification of drug preparations. The company, which was established in 2007 and maintains its headquarters in Uppsala, Sweden, officially changed its name to Perpetua Medical AB (publ) in April 2024, having formerly been known as Pharmacolog i Uppsala AB (publ). Perpetua Medical AB (publ) operates as a subsidiary entity of Nolsterby Invest AB.

CEO

Anders Hedlund

Employees

Headquarters

Uppsala

Founded

2015-06-08

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save PERP-B.ST and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

PERP-B.ST has a beta of 2.07, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Perpetua Medical AB (publ)